BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

- Submitted New Drug Application to US Food and Drug Administration for acoramidis for the treatment of transthyretin amyloid cardiomyopathy based on positive results of Phase 3 ATTRibute-CM trial,...

Related Keywords

United States ,Ukraine ,Australia ,Israel ,Gaza Strip ,Japan ,American ,Japanese ,Neil Kumar ,Brian Stephenson ,Vikram Bali ,Drug Administration ,Nasdaq ,European Medicines Agency ,Securities Exchange ,Bio Pharma Inc ,Linkedin ,American Heart Association Scientific Sessions ,Exchange Commission ,Twitter ,Company Phase ,Bridgebio Pharma Inc ,New Drug Application ,New England Journal ,Marketing Authorization Application ,Kyowa Kirin ,Blue Owl ,Bio Pharma ,Win Ratio ,Accelerated Approval ,Corporate Updates ,Full Year ,Cash Equivalents ,Marketable Securities ,Short Term Restricted ,Chief Financial Officer ,Consolidated Statements ,Months Ended December ,Ended December ,Redeemable Convertible Noncontrolling Interests ,Private Placement ,Cash Flow Information ,Noncash Investing ,Financing Information ,Restricted Cash ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Annual Report ,Bio Contact ,Markets ,